MarketCapExport financials
Applied Genetic Technologies Corporation (AGTC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Applied Genetic Technologies Corporation Income Statement 2022-2011 | AGTC
Brief overview of profit and loss at Applied Genetic Technologies Corporation
This overview is based on financial performance over the past five years. According to figures from Applied Genetic Technologies Corporation, revenue changed from 4.9 million dollars to 325 thousand dollars over five years. Overall revenue changed by −93.3%, equal to an annualized rate of about −41.8%. The decline points to a contraction in the scale of the business.
EBITDA was −5.3 million dollars at the beginning and −16.2 million dollars at the end of the period (−204.2%). Operating performance weakened relative to revenue. The EBITDA share of revenue changed from −109.9% to −4988.3%. Cost pressure reduced operating profitability.
The final result was −5.2 million dollars initially and −18.4 million dollars in the final year. The period ended with a larger loss than it began with.
Market value was $69.6 million at the start and $13.5 million at the end. The market became more cautious about the prospects of the business.
Summary assessment
The results contain several connected negative signals. The main areas of concern are lower net income, declining capitalization and limited operating profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Applied Genetic Technologies Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
13.5 M | 65.2 M | 107 M | 85.9 M | 68.8 M | 69.6 M | 138 M | 216 M | 72.4 M | - | - | - |
Shares |
45 M | 32.8 M | 21.1 M | 18.2 M | 18.1 M | 18.1 M | 17.8 M | 16.3 M | 3.57 M | 109 K | 109 K | - |
Historical Prices |
0.3 | 1.99 | 5.08 | 4.73 | 3.8 | 3.85 | 7.75 | 13.3 | 20.3 | - | - | - |
Net Income |
-18.4 M | -19.1 M | -15.5 M | -8.62 M | -4.18 M | -5.19 M | 1.78 M | 3.04 M | -4.65 M | -735 K | -1.34 M | - |
Revenue |
325 K | 500 K | 2.45 M | 2.45 M | 5.42 M | 4.85 M | 10.9 M | 12.2 M | 652 K | 515 K | 190 K | - |
Operating Income |
-17.7 M | -18.4 M | -15.1 M | -8.93 M | -4.67 M | -6.24 M | 2.38 M | 2.87 M | -4.7 M | -2.9 M | -796 K | - |
Interest Expense |
2.67 M | 1.51 M | 11 K | 446 K | -125 K | -47 K | -3 K | -2 K | -49 K | 191 K | 69 K | - |
EBITDA |
-16.2 M | -17 M | -13.8 M | -7.66 M | -3.5 M | -5.33 M | 2.95 M | 3.25 M | -4.37 M | -2.62 M | -534 K | - |
Operating Expenses |
66.5 M | 59 M | 49.4 M | 46 M | 46.6 M | 37.6 M | 49.4 M | 26.9 M | 13.7 M | 4.54 M | 3.14 M | - |
General and Administrative Expenses |
17 M | 14.6 M | 13.6 M | 12.9 M | 14.4 M | 11.4 M | 10.1 M | 8.77 M | 5.18 M | 1.4 M | 787 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Applied Genetic Technologies Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
64.9 M | - | 43.6 M | 42.9 M | 42.8 M | 42.9 M | 36.8 M | 25.9 M | 25.8 M | 25.9 M | 22.3 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18 M | 18.1 M | 18 M | 18 M | 17.2 M | 18 M | 16.5 M | 16.4 M | 15.6 M | 16.4 M | 141 K | 16 M | 15.6 M | 109 K | 109 K | 109 K | 109 K | - | - | - | - | - | - | - | - |
Net Income |
-18.4 M | - | -14.3 M | -19.1 M | -17.1 M | -19.1 M | -14.9 M | -15.5 M | -15.4 M | -15.5 M | -11.2 M | -8.62 M | -11.6 M | -8.62 M | 11.5 M | -4.18 M | 1.2 M | -4.18 M | -8.1 M | -5.19 M | -1.4 M | -5.19 M | -821 K | 2.08 M | 3.62 M | 1.78 M | 1.97 M | 3.04 M | -9.12 M | 3.04 M | -6.33 M | -4.65 M | -5.38 M | -4.65 M | -3.59 M | -4.65 M | -5.38 M | -735 K | -7.06 M | -1.43 M | -1.62 M | -1.34 M | -604 K | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | 2.45 M | 2.45 M | - | - | 2.45 M | 2.45 M | 14 M | 2.45 M | 21.3 M | 5.93 M | 14 M | 5.93 M | 3.6 M | 4.85 M | 10.3 M | 4.85 M | 8.39 M | 10.9 M | 11.8 M | 10.9 M | 12 M | 12.2 M | 11.1 M | 12.2 M | 284 K | 652 K | 705 K | 652 K | 232 K | 652 K | 705 K | 515 K | 258 K | 377 K | 116 K | 190 K | 259 K | - | - | - | - | - | - |
Operating Income |
-17.3 M | - | -13.6 M | -18.4 M | -16.4 M | -18.4 M | -14.5 M | -15.1 M | -15.1 M | -15.1 M | -11.4 M | -8.93 M | -12 M | -8.93 M | 11 M | -4.67 M | 756 K | -4.67 M | -7.7 M | -6.24 M | -1.67 M | -6.24 M | -836 K | 2.15 M | 3.39 M | 2.38 M | 1.77 M | 2.87 M | -9.21 M | 2.87 M | -6.39 M | -4.7 M | -5.41 M | -4.7 M | -3.26 M | -4.7 M | -5.41 M | -2.9 M | -1.97 M | -1.29 M | -951 K | -796 K | -560 K | - | - | - | - | - | - |
Interest Expense |
657 K | - | 667 K | 675 K | 669 K | 675 K | 330 K | 335 K | 332 K | 335 K | 4 K | -2 K | 2 K | 2 K | -10 K | -10 K | 2 K | - | -10 K | -10 K | - | -10 K | - | -10 K | - | - | -2 K | - | - | - | -2 K | - | -2 K | - | 20 K | - | - | - | 172 K | - | 20 K | - | - | - | - | - | - | - | - |
EBITDA |
-17 M | - | -12.5 M | -17.7 M | -16.1 M | -18.4 M | -13.4 M | -14.3 M | -14.7 M | -15.1 M | -10.5 M | -8.28 M | -11.7 M | -8.93 M | 12 M | -4.03 M | 1.08 M | -4.67 M | -6.88 M | -5.7 M | -1.43 M | -6.24 M | -179 K | 2.59 M | 3.59 M | 2.38 M | 2.14 M | 3.07 M | -9.12 M | 2.87 M | -6.11 M | -4.52 M | -5.32 M | -4.7 M | -3.02 M | -4.52 M | -5.32 M | -2.9 M | -1.89 M | -1.29 M | -951 K | -796 K | -560 K | - | - | - | - | - | - |
Operating Expenses |
17.3 M | - | 13.6 M | 18.4 M | 16.4 M | 18.4 M | 14.5 M | 15.1 M | 15.1 M | 15.1 M | 11.4 M | 11.4 M | 12 M | 11.4 M | 10.3 M | 10.6 M | 13.3 M | 10.6 M | 11.3 M | 11.1 M | 12 M | 11.1 M | 9.22 M | 8.78 M | 8.42 M | 8.78 M | 10.2 M | 9.32 M | 20.3 M | 9.32 M | 6.68 M | 5.35 M | 6.11 M | 5.35 M | 3.49 M | 5.35 M | 6.11 M | 3.42 M | 2.22 M | - | 1.07 M | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.46 M | - | 4.42 M | 3.99 M | 4.1 M | 3.99 M | 3.53 M | 3.3 M | 3.44 M | 3.3 M | 3.13 M | 3.3 M | 3.44 M | 3.01 M | 3.35 M | - | 3.11 M | - | - | - | - | - | - | - | 2.85 M | - | 2.36 M | 2.12 M | 3.24 M | 2.12 M | 2.57 M | 1.92 M | 1.68 M | 1.92 M | 1.36 M | 1.92 M | 1.68 M | 1.19 M | 781 K | - | 323 K | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Applied Genetic Technologies Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
USA
Russia
Niderland
Israel
Schweiz
Australia
Britain
